Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer
Driver oncogenes are investigated upfront at diagnosis using multi-CDx systems with next-generation sequencing techniques or multiplex reverse-transcriptase polymerase chain reaction assays. Additionally, from 2019, comprehensive genomic profiling (CGP) assays have been available in Japan for patien...
Saved in:
| Published in | Cancer science Vol. 115; no. 5; pp. 1656 - 1664 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
John Wiley and Sons Inc
01.05.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Driver oncogenes are investigated upfront at diagnosis using multi-CDx systems with next-generation sequencing techniques or multiplex reverse-transcriptase polymerase chain reaction assays. Additionally, from 2019, comprehensive genomic profiling (CGP) assays have been available in Japan for patients with advanced solid tumors who had completed or were expected to complete standard chemotherapy. These assays are expected to comprehensively detect the driver oncogenes, especially for patients with non-small cell lung cancer (NSCLC). However, there are no reports of nationwide research on the detection of driver oncogenes in patients with advanced NSCLC who undergo CGP assays, especially in those with undetected driver oncogenes at diagnosis. In this study, we investigated the proportion of driver oncogenes detected in patients with advanced NSCLC with undetectable driver oncogenes at initial diagnosis and in all patients with advanced NSCLC who underwent CGP assays. We retrospectively analyzed data from 986 patients with advanced NSCLC who underwent CGP assays between August 2019 and March 2022, using the Center for Cancer Genomics and Advanced Therapeutics database. The proportion of driver oncogenes newly detected in patients with NSCLC who tested negative for driver oncogenes at diagnosis and in all patients with NSCLC were investigated. Driver oncogenes were detected in 451 patients (45.7%). EGFR was the most common (16.5%), followed by KRAS (14.5%). Among the 330 patients with undetected EGFR, ALK, ROS1, and BRAF V600E mutations at diagnosis, 81 patients (24.5%) had newly identified driver oncogenes. CGP assays could be useful to identify driver oncogenes in patients with advanced NSCLC, including those initially undetected, facilitating personalized treatment. |
|---|---|
| AbstractList | Driver oncogenes are investigated upfront at diagnosis using multi-CDx systems with next-generation sequencing techniques or multiplex reverse-transcriptase polymerase chain reaction assays. Additionally, from 2019, comprehensive genomic profiling (CGP) assays have been available in Japan for patients with advanced solid tumors who had completed or were expected to complete standard chemotherapy. These assays are expected to comprehensively detect the driver oncogenes, especially for patients with non-small cell lung cancer (NSCLC). However, there are no reports of nationwide research on the detection of driver oncogenes in patients with advanced NSCLC who undergo CGP assays, especially in those with undetected driver oncogenes at diagnosis. In this study, we investigated the proportion of driver oncogenes detected in patients with advanced NSCLC with undetectable driver oncogenes at initial diagnosis and in all patients with advanced NSCLC who underwent CGP assays. We retrospectively analyzed data from 986 patients with advanced NSCLC who underwent CGP assays between August 2019 and March 2022, using the Center for Cancer Genomics and Advanced Therapeutics database. The proportion of driver oncogenes newly detected in patients with NSCLC who tested negative for driver oncogenes at diagnosis and in all patients with NSCLC were investigated. Driver oncogenes were detected in 451 patients (45.7%). EGFR was the most common (16.5%), followed by KRAS (14.5%). Among the 330 patients with undetected EGFR, ALK, ROS1, and BRAF V600E mutations at diagnosis, 81 patients (24.5%) had newly identified driver oncogenes. CGP assays could be useful to identify driver oncogenes in patients with advanced NSCLC, including those initially undetected, facilitating personalized treatment. Abstract Driver oncogenes are investigated upfront at diagnosis using multi‐CDx systems with next‐generation sequencing techniques or multiplex reverse‐transcriptase polymerase chain reaction assays. Additionally, from 2019, comprehensive genomic profiling (CGP) assays have been available in Japan for patients with advanced solid tumors who had completed or were expected to complete standard chemotherapy. These assays are expected to comprehensively detect the driver oncogenes, especially for patients with non‐small cell lung cancer (NSCLC). However, there are no reports of nationwide research on the detection of driver oncogenes in patients with advanced NSCLC who undergo CGP assays, especially in those with undetected driver oncogenes at diagnosis. In this study, we investigated the proportion of driver oncogenes detected in patients with advanced NSCLC with undetectable driver oncogenes at initial diagnosis and in all patients with advanced NSCLC who underwent CGP assays. We retrospectively analyzed data from 986 patients with advanced NSCLC who underwent CGP assays between August 2019 and March 2022, using the Center for Cancer Genomics and Advanced Therapeutics database. The proportion of driver oncogenes newly detected in patients with NSCLC who tested negative for driver oncogenes at diagnosis and in all patients with NSCLC were investigated. Driver oncogenes were detected in 451 patients (45.7%). EGFR was the most common (16.5%), followed by KRAS (14.5%). Among the 330 patients with undetected EGFR , ALK , ROS1 , and BRAF V600E mutations at diagnosis, 81 patients (24.5%) had newly identified driver oncogenes. CGP assays could be useful to identify driver oncogenes in patients with advanced NSCLC, including those initially undetected, facilitating personalized treatment. Driver oncogenes are investigated upfront at diagnosis using multi‐CDx systems with next‐generation sequencing techniques or multiplex reverse‐transcriptase polymerase chain reaction assays. Additionally, from 2019, comprehensive genomic profiling (CGP) assays have been available in Japan for patients with advanced solid tumors who had completed or were expected to complete standard chemotherapy. These assays are expected to comprehensively detect the driver oncogenes, especially for patients with non‐small cell lung cancer (NSCLC). However, there are no reports of nationwide research on the detection of driver oncogenes in patients with advanced NSCLC who undergo CGP assays, especially in those with undetected driver oncogenes at diagnosis. In this study, we investigated the proportion of driver oncogenes detected in patients with advanced NSCLC with undetectable driver oncogenes at initial diagnosis and in all patients with advanced NSCLC who underwent CGP assays. We retrospectively analyzed data from 986 patients with advanced NSCLC who underwent CGP assays between August 2019 and March 2022, using the Center for Cancer Genomics and Advanced Therapeutics database. The proportion of driver oncogenes newly detected in patients with NSCLC who tested negative for driver oncogenes at diagnosis and in all patients with NSCLC were investigated. Driver oncogenes were detected in 451 patients (45.7%). EGFR was the most common (16.5%), followed by KRAS (14.5%). Among the 330 patients with undetected EGFR , ALK , ROS1 , and BRAF V600E mutations at diagnosis, 81 patients (24.5%) had newly identified driver oncogenes. CGP assays could be useful to identify driver oncogenes in patients with advanced NSCLC, including those initially undetected, facilitating personalized treatment. An analysis of 986 advanced NSCLC patients using comprehensive genomic profiling (CGP) assays revealed that 45.7% had detectable driver oncogenes, with EGFR and KRAS being the most prevalent. Notably, among patients initially negative for specific mutations ( EGFR, ALK, ROS1, BRAF V600E), CGP assays identified new driver oncogenes in 24.5% of patients, showcasing their value in uncovering overlooked mutations for personalized treatment. |
| Author | Tokuda, Shinsaku Ishida, Masaki Katayama, Yuki Iwasaku, Masahiro Tachibana, Yusuke Morimoto, Kenji Sawada, Ryo Doi, Toshifumi Nishioka, Naoya Yamada, Tadaaki Ogura, Yuri Ishikawa, Takeshi Takayama, Koichi Kawachi, Hayato |
| AuthorAffiliation | 2 Department of Cancer Genome Medical Center Kyoto Prefectural University of Medicine Kyoto Japan 1 Department of Pulmonary Medicine, Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan |
| AuthorAffiliation_xml | – name: 2 Department of Cancer Genome Medical Center Kyoto Prefectural University of Medicine Kyoto Japan – name: 1 Department of Pulmonary Medicine, Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan |
| Author_xml | – sequence: 1 givenname: Masaki orcidid: 0000-0002-1890-7378 surname: Ishida fullname: Ishida, Masaki organization: Department of Cancer Genome Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 2 givenname: Masahiro surname: Iwasaku fullname: Iwasaku, Masahiro organization: Department of Cancer Genome Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 3 givenname: Toshifumi surname: Doi fullname: Doi, Toshifumi organization: Department of Cancer Genome Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 4 givenname: Takeshi orcidid: 0000-0002-5770-9710 surname: Ishikawa fullname: Ishikawa, Takeshi organization: Department of Cancer Genome Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 5 givenname: Yusuke surname: Tachibana fullname: Tachibana, Yusuke organization: Department of Cancer Genome Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 6 givenname: Ryo surname: Sawada fullname: Sawada, Ryo organization: Department of Cancer Genome Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 7 givenname: Yuri surname: Ogura fullname: Ogura, Yuri organization: Department of Cancer Genome Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 8 givenname: Hayato surname: Kawachi fullname: Kawachi, Hayato organization: Department of Cancer Genome Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 9 givenname: Yuki surname: Katayama fullname: Katayama, Yuki organization: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 10 givenname: Naoya surname: Nishioka fullname: Nishioka, Naoya organization: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 11 givenname: Kenji surname: Morimoto fullname: Morimoto, Kenji organization: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 12 givenname: Shinsaku surname: Tokuda fullname: Tokuda, Shinsaku organization: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 13 givenname: Tadaaki orcidid: 0000-0002-6945-281X surname: Yamada fullname: Yamada, Tadaaki organization: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 14 givenname: Koichi surname: Takayama fullname: Takayama, Koichi organization: Department of Cancer Genome Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38450844$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkU1PxCAQhonRqLt68A8YjnqoQqEfnIwxfiVGL3omLB1WTAsV2tX997LuanQOM2R45mXIO0HbzjtA6IiSM5riXKt4RkvKyBbap4yLrCKk3P4-V5kgLN9DkxjfCGElF3wX7bGaF6TmfB99PqrBevdhG8CNGhQ2wXdY-64P8Aou2gXgOTjfWY374I1trZtjFaNaRmx8wA0MoIdVswkJDtg77dMERGwdTotmsVNtizWk1I6J08ppCAdox6g2wuGmTtHLzfXz1V328HR7f3X5kGlWlUNWCSM444aCobowtABlFDBTU9EwY-qClkJUppiRggsCpOSgRG4qKkxeMVazKbpY6_bjrINGgxuCamUfbKfCUnpl5f8bZ1_l3C8kpUQwWvOkcLJRCP59hDjIzsbVd5QDP0aZC57TuhScJPR0jergYwxgft-hRK6skskq-W1VYo__LvZL_njDvgA195P5 |
| CitedBy_id | crossref_primary_10_1016_j_resinv_2024_04_022 |
| Cites_doi | 10.1056/NEJMoa2112431 10.1002/cncy.22434 10.1056/NEJMoa1408440 10.1186/s13073-017-0424-2 10.1158/2159-8290.CD-22-0417 10.1056/NEJMoa2002787 10.1016/S1470-2045(16)30146-2 10.1093/jjco/hyab059 10.1016/j.jmoldx.2017.01.011 10.1111/cas.13969 10.1056/NEJMoa1713137 10.1016/j.lungcan.2020.07.014 10.1016/j.lungcan.2014.04.009 10.3233/CBM-200781 10.1001/jamanetworkopen.2023.47700 10.1056/NEJMoa2005653 10.1200/CCI.20.00108 10.1056/NEJMoa2103695 10.1016/j.resinv.2023.08.005 10.1016/S0140-6736(17)30565-2 10.1111/1759-7714.14643 10.1016/j.cllc.2021.06.006 10.1016/j.jtho.2020.01.021 10.1016/S1470-2045(19)30690-4 10.1016/j.annonc.2021.06.001 10.1038/bmt.2012.244 10.1371/journal.pone.0237802 10.1158/1078-0432.CCR-14-2683 10.1111/cas.15176 10.1016/S1470-2045(19)30691-6 10.1038/s41598-022-17394-7 10.1200/JCO.21.01626 10.1002/gcc.22047 10.1016/j.jtho.2020.12.002 |
| ContentType | Journal Article |
| Copyright | 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2024 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |
| Copyright_xml | – notice: 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2024 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.1111/cas.16130 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Ishida et al |
| EISSN | 1349-7006 |
| EndPage | 1664 |
| ExternalDocumentID | 10_1111_cas_16130 38450844 |
| Genre | Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GrantInformation_xml | – fundername: JSPS KAKENHI grantid: 23K16334 |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 24P 29B 2WC 31~ 36B 3O- 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7.U 702 7PT 8-0 8-1 8-3 8-4 8-5 8FE 8FH 8UM 930 A01 A03 AAHHS AAZKR ABCQN ABEML ACCFJ ACSCC ACXQS ADBBV ADKYN ADZMN ADZOD AEEZP AENEX AEQDE AFBPY AFEBI AFFNX AFKRA AFPKN AFZJQ AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BFHJK BHPHI BY8 CAG CCPQU CGR COF CS3 CUY CVF D-6 D-7 D-E D-F DIK DR2 DU5 E3Z EBS ECM EIF EJD EMB EMOBN EX3 F00 F01 F04 F5P FIJ GODZA GROUPED_DOAJ HCIFZ HF~ HOLLA HYE HZI HZ~ IAO IHR IPNFZ ITC IX1 J0M K.9 K48 KQ8 LC2 LC3 LH4 LK8 LP6 LP7 LW6 M7P MK4 N04 N05 N9A NPM O9- OIG OK1 OVD P2P P2X P2Z P4B P4D PIMPY PROAC Q11 ROL RPM RX1 SJN SUPJJ SV3 TEORI UB1 W8V WIN WOW WQJ WRC WXI X7M XG1 ZXP ~IA ~WT AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c376t-79f9434f1ef1c5f15eafae3f819d3ff8516997f5b05490e064ea92f719f273383 |
| IEDL.DBID | RPM |
| ISSN | 1347-9032 |
| IngestDate | Tue Sep 17 21:28:46 EDT 2024 Sat Oct 26 05:25:08 EDT 2024 Thu Sep 26 15:42:05 EDT 2024 Sat Nov 02 12:24:31 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | driver oncogenes comprehensive genomic profiling precision medicine Center for Cancer Genomics and Advanced Therapeutics non‐small cell lung cancer |
| Language | English |
| License | 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c376t-79f9434f1ef1c5f15eafae3f819d3ff8516997f5b05490e064ea92f719f273383 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-5770-9710 0000-0002-1890-7378 0000-0002-6945-281X |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093184/ |
| PMID | 38450844 |
| PQID | 2942186940 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11093184 proquest_miscellaneous_2942186940 crossref_primary_10_1111_cas_16130 pubmed_primary_38450844 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-05-01 |
| PublicationDateYYYYMMDD | 2024-05-01 |
| PublicationDate_xml | – month: 05 year: 2024 text: 2024-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Hoboken |
| PublicationTitle | Cancer science |
| PublicationTitleAlternate | Cancer Sci |
| PublicationYear | 2024 |
| Publisher | John Wiley and Sons Inc |
| Publisher_xml | – name: John Wiley and Sons Inc |
| References | e_1_2_11_10_1 e_1_2_11_32_1 e_1_2_11_31_1 e_1_2_11_30_1 e_1_2_11_36_1 e_1_2_11_14_1 e_1_2_11_13_1 e_1_2_11_35_1 e_1_2_11_12_1 e_1_2_11_34_1 e_1_2_11_11_1 e_1_2_11_33_1 e_1_2_11_7_1 e_1_2_11_29_1 e_1_2_11_6_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_2_1 e_1_2_11_21_1 Ninomiya K (e_1_2_11_19_1) 2020; 2 e_1_2_11_20_1 e_1_2_11_25_1 e_1_2_11_24_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_18_1 e_1_2_11_17_1 e_1_2_11_16_1 e_1_2_11_15_1 e_1_2_11_37_1 |
| References_xml | – ident: e_1_2_11_12_1 doi: 10.1056/NEJMoa2112431 – ident: e_1_2_11_31_1 doi: 10.1002/cncy.22434 – ident: e_1_2_11_3_1 doi: 10.1056/NEJMoa1408440 – ident: e_1_2_11_34_1 doi: 10.1186/s13073-017-0424-2 – ident: e_1_2_11_7_1 doi: 10.1158/2159-8290.CD-22-0417 – ident: e_1_2_11_13_1 doi: 10.1056/NEJMoa2002787 – ident: e_1_2_11_6_1 doi: 10.1016/S1470-2045(16)30146-2 – ident: e_1_2_11_23_1 doi: 10.1093/jjco/hyab059 – ident: e_1_2_11_32_1 doi: 10.1016/j.jmoldx.2017.01.011 – ident: e_1_2_11_30_1 doi: 10.1111/cas.13969 – ident: e_1_2_11_2_1 doi: 10.1056/NEJMoa1713137 – ident: e_1_2_11_27_1 doi: 10.1016/j.lungcan.2020.07.014 – ident: e_1_2_11_8_1 – ident: e_1_2_11_21_1 doi: 10.1016/j.lungcan.2014.04.009 – ident: e_1_2_11_24_1 doi: 10.3233/CBM-200781 – ident: e_1_2_11_26_1 doi: 10.1001/jamanetworkopen.2023.47700 – ident: e_1_2_11_14_1 doi: 10.1056/NEJMoa2005653 – ident: e_1_2_11_9_1 doi: 10.1200/CCI.20.00108 – ident: e_1_2_11_10_1 doi: 10.1056/NEJMoa2103695 – ident: e_1_2_11_37_1 doi: 10.1016/j.resinv.2023.08.005 – ident: e_1_2_11_4_1 doi: 10.1016/S0140-6736(17)30565-2 – ident: e_1_2_11_36_1 doi: 10.1111/1759-7714.14643 – ident: e_1_2_11_28_1 doi: 10.1016/j.cllc.2021.06.006 – ident: e_1_2_11_33_1 doi: 10.1016/j.jtho.2020.01.021 – ident: e_1_2_11_5_1 doi: 10.1016/S1470-2045(19)30690-4 – ident: e_1_2_11_11_1 doi: 10.1016/j.annonc.2021.06.001 – ident: e_1_2_11_17_1 doi: 10.1038/bmt.2012.244 – ident: e_1_2_11_29_1 doi: 10.1371/journal.pone.0237802 – ident: e_1_2_11_20_1 doi: 10.1158/1078-0432.CCR-14-2683 – ident: e_1_2_11_25_1 doi: 10.1111/cas.15176 – ident: e_1_2_11_15_1 doi: 10.1016/S1470-2045(19)30691-6 – ident: e_1_2_11_35_1 doi: 10.1038/s41598-022-17394-7 – volume: 2 issue: 1 year: 2020 ident: e_1_2_11_19_1 article-title: Japanese lung cancer society guidelines for stage IV NSCLC with EGFR mutations publication-title: JTO Clin Res Rep contributor: fullname: Ninomiya K – ident: e_1_2_11_18_1 doi: 10.1200/JCO.21.01626 – ident: e_1_2_11_22_1 doi: 10.1002/gcc.22047 – ident: e_1_2_11_16_1 doi: 10.1016/j.jtho.2020.12.002 |
| SSID | ssj0036494 |
| Score | 2.4807131 |
| Snippet | Driver oncogenes are investigated upfront at diagnosis using multi-CDx systems with next-generation sequencing techniques or multiplex reverse-transcriptase... Abstract Driver oncogenes are investigated upfront at diagnosis using multi‐CDx systems with next‐generation sequencing techniques or multiplex... Driver oncogenes are investigated upfront at diagnosis using multi‐CDx systems with next‐generation sequencing techniques or multiplex reverse‐transcriptase... |
| SourceID | pubmedcentral proquest crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 1656 |
| SubjectTerms | Adult Aged Aged, 80 and over Anaplastic Lymphoma Kinase - genetics Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology ErbB Receptors - genetics Female Gene Expression Profiling - methods Genomics - methods High-Throughput Nucleotide Sequencing - methods Humans Japan Lung Neoplasms - genetics Lung Neoplasms - pathology Male Middle Aged Mutation Oncogenes - genetics Original ORIGINAL ARTICLES Protein-Tyrosine Kinases - genetics Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins p21(ras) - genetics Receptor Protein-Tyrosine Kinases - genetics Retrospective Studies |
| Title | Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38450844 https://search.proquest.com/docview/2942186940 https://pubmed.ncbi.nlm.nih.gov/PMC11093184 |
| Volume | 115 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwEB0BlRCXCkoLC3TlVlzDbmInsY-wWoQqgRAqErfI8QdE2s2i3UUVnPgJ_EZ-CTPxBnXprZccEidxPE_jN_HzDMAhF7a0QuSRSW0SCcvLqERWHUmJs6OXiKqgtrjIzq7Fr5v0ZgWydi9MI9o3ZXVUj8ZHdXXXaCvvx6bX6sR6l-cDypKJWBS9VVhFhLYxevC_PBMqlLLFHqg-Txb5hEi_Q2XEYmLMG7DOpUByIsTyhPQPy_wolvxr9jndhM8L2siOQ_e2YMXVX2D9fLEwvg1PIb_1n8o6RqJPRttGGOnFp-4uaNQZpWMdV4aFMt04ZTEkzvpxxpC3MutoNYFO2ilJNdikNpNbcoSsqlk9qV-fX2ZjPRox-tXPRugjmCHETL_C9enw9-AsWpRViAx6k3mUK09J4XzsfGxSH6dOe-24R25gufeSVs5U7tMS2ZzqO-QsTqvE57HyyHUwov0Ga_hatwssx2iNl0pankshbapzo3mWWlf2lXZZ1oGf7dgW9yF7RtFGHWiLorFFB360o14gtukrdO0mD7MiUaIpmSWwzU6wwvtjWvN1QC7Z570B5c1evoJwavJnt_DZ-_9b92EjQXYTlI8HsDafPrjvyE7mZRc-nQwvLq-6TXRPx6uk2wD0DXXC6y4 |
| link.rule.ids | 230,315,730,783,787,867,888,27936,27937,33757,53804,53806 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIpVeyhuWp0Fcs7uJncQ-oopqgW7FoRW9RfGrjdjNVvtQRU_8BH4jv4SZeF2x5QTX2ElszXj8WfP5G4B3XFhthSgTk9ssEZbrRCOqTqTE3dFL9KrAtjgqRifi02l-ugVFvAvTkfaNbvrtZNpvm_OOW3kxNYPIExt8Ge-TSib6ohjcgtu4YIcintJDBOaFUKGYLY5BDXm2VhQiBg8VEksJM-_CDpcC4YkQm1vSXzjzJl3yj_3n4C58jSMPtJNv_dVS983VDVHHf5_aPdhbQ1L2PrTfhy3XPoCd8Trp_hCugnb2ZWMdI0IpoyspjLjoc3ce-O-MpF6njWGhBDhuhwxBef19wRATM-soU0EP7ZxoIGzWmtkZBVnWtKydtb9-_FxM68mEURqBTTD-MEPeOH8EJwcfjvdHybpkQ2IwUi2TUnkSnPOp86nJfZq72teOe8QdlnsvKSunSp9rRIpq6BAPuVplvkyVRxyFp-XHsI2_dU-BlXgS5FpJy0sppM3r0tS8yK3TQ1W7oujB22i16iIoc1TxRINWrjor9-BNtGeF64ZmUbdutlpUmRJdOS6BfZ4E-15_JjpGD-SG5a87kCb3Zgvas9PmjvZ79v-vvoY7o-PxYXX48ejzc9jNEEUFhuUL2F7OV-4loqClftW5_G_8Lgnn |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSKteoLzKlgIGcc3uJnYS-4gKq_Jo1QOVKnGI_Gyj7npX-1BFT_wEfiO_hJk4qdhy6zVxElsznvms-fINIe8Zt9pyXiYmt1nCLdOJBlSdCAHZ0Qvwqsi2OC4OT_mXs_ysZVUuW1plMLoehMl0EOqLhls5n5phxxMbnhwdoEom-CIfzq0f3icPYNOOiu6kHqMwK7iMDW1hHnLEslZVCFk82EwsRdy8TXpMcIAonG-mpf-w5m3K5D85aPyI_OhmH6knl4P1Sg_M9S1hx7stb4c8bKEp_RDHPCb3XHhCekdt8f0puY4a2le1dRSJpRR_TaHISV-4i8iDpyj5Oq0Nja3AIS1SAOfq55ICNqbWYcUCL9oF0kHoLJjZOQZbWgcaZuHPr9_LqZpMKJYT6ATiEDXolYtn5HT86fvBYdK2bkgMRKxVUkqPwnM-dT41uU9zp7xyzAP-sMx7gdU5WfpcA2KUIwe4yCmZ-TKVHvAUnJqfky34rHtBaAknQqalsKwUXNhclUaxIrdOj6RyRdEn7zrLVfOo0FF1JxuwdNVYuk_edjatYP_gKlRws_WyyiRv2nJxGLMbbXzzms45-kRsWP9mAGpzb94BmzYa3Z0N9-7-6BvSO_k4rr59Pv76kmxnAKYi0XKfbK0Wa_cKwNBKv268_i83_Axn |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nationwide+data+from+comprehensive+genomic+profiling+assays+for+detecting+driver+oncogenes+in+non-small+cell+lung+cancer&rft.jtitle=Cancer+science&rft.au=Ishida%2C+Masaki&rft.au=Iwasaku%2C+Masahiro&rft.au=Doi%2C+Toshifumi&rft.au=Ishikawa%2C+Takeshi&rft.date=2024-05-01&rft.eissn=1349-7006&rft.volume=115&rft.issue=5&rft.spage=1656&rft.epage=1664&rft_id=info:doi/10.1111%2Fcas.16130&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon |